CannaPharmaRX, Inc. Logo

CannaPharmaRX, Inc.

CPMD

(2.5)
Stock Price

0,01 USD

5.35% ROA

-8.01% ROE

8.6x PER

Market Cap.

5.432.508,00 USD

-82.37% DER

0% Yield

408.25% NPM

CannaPharmaRX, Inc. Stock Analysis

CannaPharmaRX, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

CannaPharmaRX, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (50.76%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 PBV

The stock's low PBV ratio (-0.03x) suggests it's undervalued, making it an attractive opportunity for investors.

3 DER

The stock has a low debt to equity ratio (-79%), which means it has a small amount of debt compared to the ownership it holds

4 Net Profit Growth

Over the last five years, this company's net profit has shown continuous growth, reflecting a robust financial performance and making it an attractive choice for potential investors.

5 Revenue Growth

Over the past three years, this company's revenue has consistently grown, demonstrating a positive financial trend that makes it an appealing choice.

6 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

7 ROA

The stock's ROA (-168.51%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

CannaPharmaRX, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

CannaPharmaRX, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

CannaPharmaRX, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

CannaPharmaRX, Inc. Revenue
Year Revenue Growth
1998 0
1999 620.000 100%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

CannaPharmaRX, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1998 0
1999 590.000 100%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 589.783 100%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

CannaPharmaRX, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1998 10.000
1999 2.930.000 99.66%
2006 0 0%
2007 111.783 100%
2008 200.327 44.2%
2009 93.562 -114.11%
2010 91.389 -2.38%
2011 97.102 5.88%
2012 89.568 -8.41%
2013 80.311 -11.53%
2014 1.437.204 94.41%
2015 11.059.883 87.01%
2016 1.004.891 -1000.61%
2017 6.633 -15049.87%
2018 532.772 98.76%
2019 2.851.340 81.32%
2020 4.509.670 36.77%
2021 2.613.762 -72.54%
2022 4.905.989 46.72%
2023 2.363.788 -107.55%
2023 838.246 -181.99%
2024 1.129.300 25.77%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

CannaPharmaRX, Inc. EBITDA
Year EBITDA Growth
1998 -70.000
1999 -4.220.000 98.34%
2006 -76.124 -5443.59%
2007 -14.348.061 99.47%
2008 -200.327 -7062.32%
2009 -93.563 -114.11%
2010 585.600 115.98%
2011 -97.102 703.08%
2012 -89.568 -8.41%
2013 -80.311 -11.53%
2014 -76.467 -5.03%
2015 -11.446.883 99.33%
2016 -1.000.827 -1043.74%
2017 -6.633 -14988.6%
2018 -532.709 98.75%
2019 -2.851.340 81.32%
2020 -4.509.671 36.77%
2021 -2.613.762 -72.54%
2022 -4.514.481 42.1%
2023 -1.822.092 -147.76%
2023 -1.447.335 -25.89%
2024 -1.813.760 20.2%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

CannaPharmaRX, Inc. Gross Profit
Year Gross Profit Growth
1998 0
1999 130.000 100%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 -12.031 100%
2016 0 0%
2017 0 0%
2018 0 0%
2019 -129.035 100%
2020 -128.505 -0.41%
2021 -14.364 -794.63%
2022 -294.934 95.13%
2023 -48 -614345.83%
2023 -65.561 99.93%
2024 -256.948 74.48%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

CannaPharmaRX, Inc. Net Profit
Year Net Profit Growth
1998 -40.000
1999 -4.750.000 99.16%
2006 9.607 49543.11%
2007 7.113.891 99.86%
2008 -201.590 3628.89%
2009 108.863 285.18%
2010 575.404 81.08%
2011 -99.661 677.36%
2012 -98.067 -1.63%
2013 -94.406 -3.88%
2014 -3.978.433 97.63%
2015 -11.742.932 66.12%
2016 -1.001.250 -1072.83%
2017 -6.633 -14994.98%
2018 -3.094.306 99.79%
2019 -24.924.217 87.59%
2020 -22.184.130 -12.35%
2021 -10.339.890 -114.55%
2022 -8.531.020 -21.2%
2023 -2.257.472 -277.9%
2023 3.688.456 161.2%
2024 21.449.056 82.8%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

CannaPharmaRX, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1998 0
1999 -2 100%
2006 0 0%
2007 3 100%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 -1 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 -1 0%
2020 -1 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

CannaPharmaRX, Inc. Free Cashflow
Year Free Cashflow Growth
1998 -10.000
1999 -3.560.000 99.72%
2006 0 0%
2007 -106.828 100%
2008 -62.483 -70.97%
2009 -69.123 9.61%
2010 -60.000 -15.21%
2011 -12.104 -395.7%
2012 -10.913 -10.91%
2013 -11.017 0.94%
2014 -1.641.827 99.33%
2015 -2.550.837 35.64%
2016 -22.380 -11297.84%
2017 0 0%
2018 -941.136 100%
2019 -3.841.708 75.5%
2020 -563.573 -581.67%
2021 -2.420.919 76.72%
2022 -1.564.362 -54.75%
2023 119.696 1406.95%
2023 -2.355.086 105.08%
2024 -427.616 -450.75%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

CannaPharmaRX, Inc. Operating Cashflow
Year Operating Cashflow Growth
1998 -10.000
1999 -3.350.000 99.7%
2006 0 0%
2007 -106.828 100%
2008 -62.483 -70.97%
2009 -69.123 9.61%
2010 -60.000 -15.21%
2011 -12.104 -395.7%
2012 -10.913 -10.91%
2013 -11.017 0.94%
2014 -1.541.106 99.29%
2015 -2.548.759 39.54%
2016 -22.380 -11288.56%
2017 0 0%
2018 -941.136 100%
2019 -3.794.771 75.2%
2020 -563.573 -573.34%
2021 -2.414.656 76.66%
2022 -1.448.364 -66.72%
2023 123.876 1269.2%
2023 -2.274.452 105.45%
2024 -427.616 -431.89%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

CannaPharmaRX, Inc. Capital Expenditure
Year Capital Expenditure Growth
1998 0
1999 210.000 100%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 100.721 100%
2015 2.078 -4747.02%
2016 0 0%
2017 0 0%
2018 0 0%
2019 46.937 100%
2020 0 0%
2021 6.263 100%
2022 115.998 94.6%
2023 4.180 -2675.07%
2023 80.634 94.82%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

CannaPharmaRX, Inc. Equity
Year Equity Growth
1998 1.990.000
1999 7.170.000 72.25%
2006 -7.945.944 190.23%
2007 -584.998 -1258.29%
2008 -685.167 14.62%
2009 -576.304 -18.89%
2010 100 576404%
2011 -99.561 100.1%
2012 -197.628 49.62%
2013 -292.034 32.33%
2014 -288.230 -1.32%
2015 -684.542 57.89%
2016 -957.667 28.52%
2017 -964.300 0.69%
2018 -286.299 -236.82%
2019 4.854.198 105.9%
2020 -8.801.599 155.15%
2021 -12.925.920 31.91%
2022 -17.344.455 25.48%
2023 -20.629.975 15.93%
2023 -12.153.213 -69.75%
2024 -16.668.523 27.09%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

CannaPharmaRX, Inc. Assets
Year Assets Growth
1998 2.270.000
1999 9.600.000 76.35%
2006 198 -4848384.85%
2007 6.187 96.8%
2008 0 0%
2009 0 0%
2010 100 100%
2011 25 -300%
2012 25 0%
2013 0 0%
2014 1.797.042 100%
2015 12.059 -14802.08%
2016 1.667 -623.4%
2017 190.000 99.12%
2018 10.098.081 98.12%
2019 16.017.414 36.96%
2020 8.747.591 -83.11%
2021 114.330 -7551.18%
2022 5.414.176 97.89%
2023 5.155.989 -5.01%
2023 11.745.650 56.1%
2024 11.713.765 -0.27%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

CannaPharmaRX, Inc. Liabilities
Year Liabilities Growth
1998 290.000
1999 2.430.000 88.07%
2006 7.946.142 69.42%
2007 591.185 -1244.1%
2008 685.167 13.72%
2009 576.304 -18.89%
2010 0 0%
2011 99.586 100%
2012 197.653 49.62%
2013 292.034 32.32%
2014 2.085.272 86%
2015 696.601 -199.35%
2016 959.334 27.39%
2017 964.300 0.51%
2018 10.384.380 90.71%
2019 11.163.216 6.98%
2020 17.549.190 36.39%
2021 13.040.250 -34.58%
2022 22.758.631 42.7%
2023 25.785.964 11.74%
2023 23.898.863 -7.9%
2024 28.382.288 15.8%

CannaPharmaRX, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
0
Price to Earning Ratio
8.6x
Price To Sales Ratio
209.98x
POCF Ratio
-2.5
PFCF Ratio
-2.51
Price to Book Ratio
-0.32
EV to Sales
740.33
EV Over EBITDA
-10.1
EV to Operating CashFlow
-8.88
EV to FreeCashFlow
-8.86
Earnings Yield
0.12
FreeCashFlow Yield
-0.4
Market Cap
0,01 Bil.
Enterprise Value
0,02 Bil.
Graham Number
0.02
Graham NetNet
-0.04

Income Statement Metrics

Net Income per Share
0
Income Quality
-3.44
ROE
-0.03
Return On Assets
0.12
Return On Capital Employed
0.16
Net Income per EBT
1
EBT Per Ebit
-0.78
Ebit per Revenue
-5.2
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
23.17
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
-3.5
Gross Profit Margin
-2.61
Operating Profit Margin
-5.2
Pretax Profit Margin
4.08
Net Profit Margin
4.08

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0
Free CashFlow per Share
-0
Capex to Operating CashFlow
-0
Capex to Revenue
0.23
Capex to Depreciation
0.03
Return on Invested Capital
0.31
Return on Tangible Assets
0.05
Days Sales Outstanding
3812.64
Days Payables Outstanding
5543.77
Days of Inventory on Hand
823.28
Receivables Turnover
0.1
Payables Turnover
0.07
Inventory Turnover
0.44
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
-0,03
Tangible Book Value per Share
-0.03
Shareholders Equity per Share
-0.03
Interest Debt per Share
0.02
Debt to Equity
-0.82
Debt to Assets
1.17
Net Debt to EBITDA
-7.23
Current Ratio
0.07
Tangible Asset Value
-0,02 Bil.
Net Current Asset Value
-0,03 Bil.
Invested Capital
-15552300
Working Capital
-0,02 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,01 Bil.
Average Inventory
1096028.5
Debt to Market Cap
2.53

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

CannaPharmaRX, Inc. Dividends
Year Dividends Growth

CannaPharmaRX, Inc. Profile

About CannaPharmaRX, Inc.

CannaPharmaRX, Inc. operates in the cannabis industry in Canada. It negotiates, acquires, and develops various cannabis cultivation projects. The company was incorporated in 1998 and is based in Calgary, Canada.

CEO
Mr. Oliver W. Foeste C.A., C.P
Employee
21
Address
888 3rd Street SW
Calgary, T2P 5C5

CannaPharmaRX, Inc. Executives & BODs

CannaPharmaRX, Inc. Executives & BODs
# Name Age
1 Mr. Oliver W. Foeste C.A., C.P.A.
Chief Financial Officer
70

CannaPharmaRX, Inc. Competitors